VBL   Report issue

For profit Phase 2 Phase 3
Founded: Modi'in Israel (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2007
NCT00559117
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Vascular Biogenics Ltd. operating as VBL Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (3)

bevacizumab (avastin) (3 trials)

Ofranergene obadenovec (5 trials)

paclitaxel (taxol) (2 trials)

Drugs in Phase 2 Trials (2)

vb11 (1 trial)

vb-201 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 3)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Glioblastoma (Phase 3)

Neoplasm Metastasis (Phase 1)

Ovarian Neoplasms (Phase 3)

Psoriasis (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 5